Terms: = Endocrine gland cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
701 results:
1. Polycyclic Aromatic Hydrocarbons and Pancreatic cancer: An Analysis of the Blood Biomarker,
Nguyen S; Carlson H; Yoder A; Bamlet WR; Oberg AL; Petersen GM; Carmella SG; Hecht SS; Jansen RJ
Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474816
[TBL] [Abstract] [Full Text] [Related]
2. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
4. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer.
Ishizaki S; Furukawa K; Haruki K; Tsunematsu M; Shirai Y; Matsumoto M; Okui N; Onda S; Taniai T; Ikegami T
Pancreatology; 2024 Mar; 24(2):249-254. PubMed ID: 38218681
[TBL] [Abstract] [Full Text] [Related]
6. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
7. The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.
Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Mizukami H; Fujiwara H
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1934. PubMed ID: 38013666
[TBL] [Abstract] [Full Text] [Related]
8. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
9. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.
Melisi D; Zecchetto C; Merz V; Malleo G; Landoni L; Quinzii A; Casalino S; Fazzini F; Gaule M; Pesoni C; Casetti L; Esposito A; Marchegiani G; Piazzola C; D'Onofrio M; de Robertis R; Gabbrielli A; Bernardoni L; Crino SF; Pietrobono S; Luchini C; Aliberti C; Martignoni G; Milleri S; Butturini G; Scarpa A; Salvia R; Bassi C
Eur J Cancer; 2024 Jan; 196():113430. PubMed ID: 37995598
[TBL] [Abstract] [Full Text] [Related]
10. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review.
Taliento C; Restaino S; Scutiero G; Arcieri M; Bernardi G; Martinello R; Driul L; Perrone AM; Fagotti A; Scambia G; Greco P; Vizzielli G
Eur J Surg Oncol; 2023 Dec; 49(12):107250. PubMed ID: 37951158
[TBL] [Abstract] [Full Text] [Related]
11. Age-stratified comparison of active surveillance versus radiofrequency ablation for papillary thyroid microcarcinoma using decision analysis.
Carlisle KM; Brown JP; Kim J; Turner DJ; Slejko JF; Kuo JH; Mullins CD; Hu Y
Surgery; 2024 Jan; 175(1):153-160. PubMed ID: 37872047
[TBL] [Abstract] [Full Text] [Related]
12. Laparoscopic Management of Blunt Pancreatic Trauma in Adults and Pediatric Patients: A Systematic Review.
Catellani B; Caracciolo D; Magistri P; Guidetti C; Menduni N; Yu H; Odorizzi R; Guerrini GP; Ballarin R; Di Sandro S; Di Benedetto F
Biomed Res Int; 2023; 2023():9296570. PubMed ID: 37810623
[TBL] [Abstract] [Full Text] [Related]
13. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA; Melisi D; Macarulla T; Pazo Cid R; Chandana SR; De La Fouchardière C; Dean A; Kiss I; Lee WJ; Goetze TO; Van Cutsem E; Paulson AS; Bekaii-Saab T; Pant S; Hubner RA; Xiao Z; Chen H; Benzaghou F; O'Reilly EM
Lancet; 2023 Oct; 402(10409):1272-1281. PubMed ID: 37708904
[TBL] [Abstract] [Full Text] [Related]
14. Effects of Ultrasound-Guided Laser Ablation Therapy on Symptomatic Benign Thyroid Nodules, Using EchoLaser - Results of a Pilot Study in the United States.
Thomas J; Ledger GA; Haertling T
Endocr Pract; 2023 Dec; 29(12):942-947. PubMed ID: 37704167
[TBL] [Abstract] [Full Text] [Related]
15. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
[TBL] [Abstract] [Full Text] [Related]
16. Corticotropin releasing factor-1 receptor antagonism associated with favorable outcomes of male reproductive health biochemical parameters.
Khattab A; Charlton RW
Front Endocrinol (Lausanne); 2023; 14():1127558. PubMed ID: 37284216
[TBL] [Abstract] [Full Text] [Related]
17. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract] [Full Text] [Related]
18. Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas.
Mo S; Zou L; Hu Y; Chang X; Chen J
Mod Pathol; 2023 Sep; 36(9):100223. PubMed ID: 37244388
[TBL] [Abstract] [Full Text] [Related]
19. Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study.
Schofield C; Newton RU; Taaffe DR; Galvão DA; Cohen PA; Meniawy TM; Peddle-McIntyre CJ
Support Care Cancer; 2023 Apr; 31(5):304. PubMed ID: 37101013
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNIcancer PRODIGE 23): Health-related quality of life longitudinal analysis.
Bascoul-Mollevi C; Gourgou S; Borg C; Etienne PL; Rio E; Rullier E; Juzyna B; Castan F; Conroy T
Eur J Cancer; 2023 Jun; 186():151-165. PubMed ID: 37068407
[TBL] [Abstract] [Full Text] [Related]
[Next]
